Single-cell Analysis Market Report 2026

The single-cell analysis market size has grown rapidly in recent years. It will grow from $3.93 billion in 2025 to $4.54 billion in 2026 at a compound annual growth rate (CAGR) of 15.4%. The growth in the historic period can be attributed to advancements in genomic research tools, expansion of cancer research programs, increasing funding for life sciences research, growing adoption of next generation sequencing, rising academic research activities.

The single-cell analysis market size is expected to see rapid growth in the next few years. It will grow to $8.21 billion in 2030 at a compound annual growth rate (CAGR) of 16%. The growth in the forecast period can be attributed to increasing investments in precision medicine, expansion of single-cell applications in drug discovery, rising use in clinical research, growing adoption of ai-driven biological analysis, increasing demand for personalized therapeutics. Major trends in the forecast period include increasing adoption of high-throughput single-cell sequencing, rising integration of multi-omics analysis, growing use of ai in cell data interpretation, expansion of automated single-cell workflows, enhanced focus on translational research.

The rising emphasis on personalized medicine worldwide is driving the expansion of the single-cell analysis market. Personalized medicine is a medical approach that utilizes an individual's genetic profile to inform decisions regarding the treatment, prevention, and diagnosis of diseases specific to that person. Single-cell analysis plays a crucial role in treating various conditions by providing detailed insights into individual patient needs, the nature of the disease, and tailored treatment options. As a result, more patients are choosing personalized medicine for their care. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit, reported that the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Consequently, the growing focus on personalized medicine is fueling market growth.

Leading companies in the single-cell analysis field are focusing on developing advanced clinical diagnostic tools, such as high-precision single-cell RNA-sequencing kits, to enhance the accuracy and depth of gene-expression analysis. High-precision single-cell RNA-sequencing kits are specialized instruments designed to precisely capture and examine gene expression at the level of individual cells, enabling researchers to reveal cellular diversity, detect rare cell types, and gain deeper understanding of biological processes and disease mechanisms. For example, in June 2024, Bio-Rad, a US-based global leader in life science research and clinical diagnostics, launched the Single-Cell 3’ RNA-Seq Kit for single-cell gene expression. This kit is specifically designed for high-throughput sequencing of gene expression from individual cells, targeting the 3' end of mRNA transcripts, which allows researchers to analyze and quantify gene expression profiles in single cells. It is extensively used in studies of cellular heterogeneity, developmental biology, and disease mechanisms, providing valuable insights into complex biological systems and driving advancements in single-cell analysis.

In July 2023, Illumina, Inc., a US-based biotechnology company, acquired Fluent BioSciences for an undisclosed amount. The purpose of this acquisition is to enhance Illumina's capabilities in single-cell analysis and expand its multiomics growth strategy by integrating Fluent BioSciences' innovative and accessible technology. Fluent BioSciences, also based in the US, focuses on advancing technologies for single-cell analysis, with a particular emphasis on creating scalable and innovative solutions that facilitate genomic research and enable researchers to conduct detailed studies at the single-cell level.

Major companies operating in the single-cell analysis market include Becton Dickinson and Company, Merck KGAA, QIAGEN N. V., Thermo Fisher Scientific Inc., Illumina Inc., Standard BioTools Inc., 10X Genomics Inc., Bio-Rad Laboratories Inc., Novogene Corporation Limited, Agilent Technologies Inc., Sartorius AG, Luminex Corporation, Fluxion Biosciences Inc., Oxford Nanopore Technologies Ltd., 1CellBio Inc., 3D Biomatrix Inc., ACEA Biosciences Inc., Akoya Biosciences Inc., Berkeley Lights Inc., Bio-Techne Corporation, Celsee Inc., Cellular Research Inc., Cytena GmbH, Dolomite Bio Limited, Drop-seq Technologies Inc., Epic Sciences Inc., Ginkgo Bioworks Inc., IsoPlexis Corporation, Menarini Silicon Biosystems S. p. A., Mission Bio Inc., NanoCellect Biomedical Inc., NemaMetrix Inc., OnRamp Bioinformatics Inc., Partek Incorporated, RareCyte Inc., Scienion AG, SeqWell Inc., Sphere Fluidics Limited, Takara Bio USA Holdings Inc.

North America was the largest region in the single-cell analysis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the single-cell analysis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the single-cell analysis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The single-cell analysis market includes revenues earned by entities by providing services such as antibody-based methods, fluorescent protein-based methods, and mass-spectroscopy based methods. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.